Stoke Therapeutics Completes Enrollment Of 162 Patients Into Phase 3 EMPEROR Study Of Zorevunersen; Co Plans To Initiate Rolling NDA Submiss
Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027 to complete the rolling U.S. NDA submission in the second half of 2027— Stoke Therapeutics, Inc. (NASDAQ: STOK ) is a biotechnology company dedicated to restor